• Merck Manual
• >
• Health Care Professionals
• >
• Endocrine and Metabolic Disorders
• >
• Pituitary Disorders
4

Galactorrhea is lactation in men or in women who are not breastfeeding. It is generally due to a prolactin-secreting pituitary adenoma. Diagnosis is by measurement of prolactin levels and imaging tests. Treatment involves tumor inhibition with dopamine agonist drugs and sometimes removal or destruction of the adenoma.

Etiology

Galactorrhea is generally due to a prolactin-secreting pituitary adenoma (prolactinoma). Most tumors in women are microadenomas (< 10 mm in diameter), but a small percentage are macroadenomas (> 10 mm) when diagnosed. The frequency of microadenomas is much lower in men, perhaps because of later recognition.

Hyperprolactinemia and galactorrhea also may be caused by ingestion of certain drugs, including phenothiazines, other anitpsychotics, certain antihypertensives (especially α-methyldopaSome Trade Names
ALDOMET
Click for Drug Monograph
), and opioids. Primary hypothyroidism can cause hyperprolactinemia and galactorrhea, because increased levels of thyroid-releasing hormone increase secretion of prolactin as well as thyroid-stimulating hormone (TSH). It is unclear why hyperprolactinemia is associated with hypogonadotropism and hypogonadism. Causes of hyperprolactinemia are listed in Table 3: Pituitary Disorders: Causes of Hyperprolactinemia.

Table 3
Causes of Hyperprolactinemia Cause Example Physiologic Nipple stimulation in women Pregnancy Postpartum period Stress Food ingestion Sexual intercourse in some women Sleep Hypoglycemia Early infancy (up to 3 mo) Hypothalamic disorders Hypothalamic tumors Nontumerous hypothalamic infiltration: Sarcoidosis, TB, Langerhans' cell histiocytosis (Hand-Schüller-Chrisitan disease) Postencephalitis Idiopathic galactorrhea (presumed abnormality in dopamine secretion) Head trauma Pituitary disorders Prolactin-secreting pituitary tumors Tumors causing pituitary stalk compression Surgical pituitary stalk section and other stalk lesions Empty sella syndrome Other endocrine disorders Acromegaly Cushing's disease Primary hypothyroidism Disorders of other systems Chronic renal failure Liver disease Ectopic production of prolactin: Bronchogenic carcinoma (not squamous cell; mostly small cell undifferentiated) Hypernephroma Chest wall lesions Surgical scars Trauma Tumors Herpes zoster Pharmacologic Antihypertensive drugs: Resperine, α-methyldopaSome Trade Names ALDOMET Click for Drug Monograph , labetalolSome Trade Names NORMODYNE TRANDATE Click for Drug Monograph , atenololSome Trade Names TENORMIN Click for Drug Monograph , verapamilSome Trade Names CALAN ISOPTIN Click for Drug Monograph , clonidineSome Trade Names CATAPRES Click for Drug Monograph H2-antagonists (eg, ranitidineSome Trade Names ZANTAC Click for Drug Monograph ) Oral contraceptives and estrogensSome Trade Names PREMARIN Click for Drug Monograph Opioids Psychoactive drugs: Eg, phenothiazines, tricyclic and some other antidepressants, butyrphenones (haloperidolSome Trade Names HALDOL Click for Drug Monograph ), benzamides (metoclopramideSome Trade Names REGLAN Click for Drug Monograph , sulpiride) Thyrotropin-releasing hormone Data from Rebar RW: Practical evaluation of hormonal status. In Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, edited by SSC Yen and RB Jaffe. Philadelphia, WB Saunders Company, 1978, p. 493.

Symptoms and Signs

Abnormal lactation is not defined quantitatively; it is milk release that is inappropriate, persistent, or worrisome to the patient. Spontaneous lactation is more unusual than milk released in response to manual expression. The milk is white. Women with galactorrhea commonly also have amenorrhea or oligomenorrhea. Women with galactorrhea and amenorrhea may also have symptoms and signs of estrogen deficiency, including dyspareunia, due to inhibition of pulsatile luteinizing hormone and follicle-stimulating hormone release by high prolactin levels. However, estrogen production may be normal, and signs of androgen excess have been observed in some women with hyperprolactinemia. Hyperprolactinemia may occur with other menstrual cycle disturbances besides amenorrhea, including infrequent ovulation and corpus luteum dysfunction.

Men with prolactin-secreting pituitary tumors typically have headaches or visual difficulties. About two thirds of affected men have loss of libido and erectile dysfunction.

Diagnosis

• Prolactin levels
• Thyroxine (T₄) and TSH levels
• CT or MRI

Diagnosis of galactorrhea due to a prolactin-secreting pituitary adenoma is based on elevated prolactin levels. In general, prolactin levels correlate with the size of a pituitary tumor and can be used to follow patients over time. Serum gonadotropin and estradiol levels are either low or in the normal range in women with hyperprolactinemia. Primary hypothyroidism is easily ruled out by absence of elevated TSH.

High-resolution CT or MRI is the method of choice in identifying microadenomas. Visual field examination is indicated in all patients with macroadenomas and in any patient who elects drug therapy or surveillance only.

Treatment

• Depends on cause, symptoms, and other factors

The treatment of microprolactinomas is controversial. Asymptomatic patients who have prolactin levels < 100 ng/mL and normal CT or MRI results or who have only microadenomas can probably be observed; serum prolactin often normalizes within years. Patients with hyperprolactinemia should be monitored with quarterly measurement of prolactin levels and undergo sellar CT or MRI annually for at least an additional 2 yr. The frequency of sellar imaging can then be reduced if prolactin levels do not increase. Indications for treatment in women include the desire for pregnancy, amenorrhea or significant oligomenorrhea (because of the risk of osteoporosis), hirsutism, low libido, and troublesome galactorrhea. Indications in men include hypogonadism (because of the risk of osteoporosis), erectile dysfunction, low libido, and troublesome infertility.

The initial treatment is usually a dopamine agonist such as bromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
(1.25 to 5 mg po bid) or the longer-acting cabergolineSome Trade Names
DOSTINEX
Click for Drug Monograph
(0.25 to 1.0 mg po once/wk or twice/wk). CabergolineSome Trade Names
DOSTINEX
Click for Drug Monograph
is the treatment of choice because it appears to be more easily tolerated and more potent than bromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
. Women trying to become pregnant should switch to bromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
at least 1 mo before planned conception and stop bromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
use at the time of a positive pregnancy test; long-term safety data are better established for bromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
than for cabergolineSome Trade Names
DOSTINEX
Click for Drug Monograph
. Exogenous estrogen can be given to women with a microadenoma who are clinically hypoestrogenic or have low estradiol levels. Exogenous estrogen is unlikely to cause tumor expansion.

Patients with macroadenomas generally should be treated with dopamine agonists or surgically but only after thorough testing of pituitary function and evaluation for radiation therapy. Dopamine agonists are usually the initial treatment of choice and usually shrink the tumor. If prolactin levels fall and symptoms and signs of compression by the tumor abate, no other therapy may be necessary. Surgery or radiation therapy may be easier to do or yield better results after tumor shrinkage induced by a dopamine agonist. Although dopamine agonist treatment usually needs to be continued long-term, prolactin-secreting tumors sometimes remit, either spontaneously or perhaps aided by the drug therapy. Sometimes, therefore, dopamine agonists can be stopped without a recurrence of the tumor or a rise in prolactin levels; remission is more likely with microadenomas than macroadenomas. Remission is also more likely after pregnancy.

High doses of dopamine antagonists, particularly cabergolineSome Trade Names
DOSTINEX
Click for Drug Monograph
and pergolideSome Trade Names
PERMAX

, are thought to have caused valvular heart disease in some patients with Parkinson's disease. It is not clear whether the lower doses of dopamine agonists used for hyperprolactinemia similarly increase the risk of valvular heart disease, but the possibility should be discussed with patients, and echocardiographic surveillance should be considered. The risk may be less with bromocriptineSome Trade Names
PARLODEL
Click for Drug Monograph
or a nonergot-derived dopamine agonist (eg, quinagolide).

Radiation therapy should be used only in patients with progressive disease who do not respond to other forms of therapy. With irradiation, hypopituitarism often develops several years after therapy. Monitoring endocrine function and sellar imaging are indicated yearly for life.

Last full review/revision February 2007 by Ian M. Chapman, MBBS, PhD

Content last modified April 2010